戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 re not significantly different compared with alpha-myosin.
2 h are specific for the cardiomyocyte protein alpha-myosin.
3 ed by chimeric myosin was similar to that of alpha-myosin, almost twice the velocities observed with
4 deficient mice was consistent with decreased alpha myosin and increased beta myosin heavy chains, sug
5                                              alpha-Myosin and beta-myosin isoform mRNAs were affected
6 tion increased the actin-sliding velocity of alpha-myosin by 20% and beta-myosin by 36% compared with
7 tion increased the actin sliding velocity of alpha-myosin by 20% and beta-myosin by 36%, compared to
8                              Moreover, these alpha-myosin-expanded T cells shared TCR clonotypes with
9 us (AdMYH6) to deliver the full-length human alpha-myosin gene to adult rabbit and human cardiac myoc
10 r peroxisome proliferator-activated receptor-alpha (myosin heavy chain [MHC]-PPARalpha mice) exhibit
11  of atrial myosin light chain 2 (MLC-2a) and alpha myosin heavy chain (alpha-MHC).
12 s accompanied by repression of genes such as alpha myosin heavy chain (alphaMyHC) and SERCA2A and the
13   In mice, CD4+ T cells specific for cardiac alpha myosin heavy chain (alphaMYHC) cause myocarditis a
14 r the control of the cardiac muscle-specific alpha myosin heavy chain (MHC) gene promoter.
15 evealed significantly elevated expression of alpha myosin heavy chain (MHC) isoform in epicardial fib
16 rated increased heart-to-body weight ratios, alpha myosin heavy chain and cardiac isoprostane levels,
17        Our results demonstrate that the beta-alpha myosin heavy chain intergenic DNA possesses a bidi
18 on of Gata4 by Cre recombinase driven by the alpha myosin heavy chain promoter did not selectively af
19                                    Using the alpha myosin heavy chain promoter to target expression o
20 s CAG promoter or the cardiomyocyte-specific alpha myosin heavy chain promoter, we identify a rare po
21  targeted manner in the heart using a murine alpha myosin heavy chain promoter.
22  and validated a new transgenic mouse, aMHC (alpha myosin heavy chain)-MerDreMer-Ki67p-RoxedCre (deno
23  validated a new transgenic mouse, alphaMHC (alpha myosin heavy chain)-MerDreMer-Ki67p-RoxedCre (deno
24 ic overexpression of JunD via the alpha MHC (alpha- myosin heavy chain) promoter (alpha MHC JunD(tg))
25  by an Arg403-->Gln missense mutation in the alpha-myosin heavy chain (403) is affected by chronicall
26 ional assays, PURalpha and PURbeta repressed alpha-myosin heavy chain (alpha-MHC) gene expression in
27  AMP-inducible expression of the rat cardiac alpha-myosin heavy chain (alpha-MHC) gene in cardiac myo
28 ible E-box/M-CAT hybrid motif in the cardiac alpha-myosin heavy chain (alpha-MHC) gene promoter.
29 R)-beta (Delta337T-TR-beta(1)) driven by the alpha-myosin heavy chain (alpha-MHC) gene promoter.
30 onstruct was under the control of the murine alpha-myosin heavy chain (alpha-MHC) promoter, and ion c
31 FATP)1 in the heart under the control of the alpha-myosin heavy chain (alpha-MHC) promoter.
32 sing PPARgamma1 in the heart via the cardiac alpha-myosin heavy chain (alpha-MHC) promoter.
33 ult cardiomyocytes in mice primarily express alpha-myosin heavy chain (alpha-MHC, also known as Myh6)
34                                          The alpha-myosin heavy chain (alpha-MyHC) is the major contr
35 inned cardiac myocytes that contained either alpha-myosin heavy chain (alpha-MyHC) or beta-MyHC at 12
36 he mouse heart, which contains predominantly alpha-myosin heavy chain (alpha-MyHC), the applicability
37  (beta-MyHC) and reduced expression of adult alpha-myosin heavy chain (alpha-MyHC), with the net outc
38 (sACT) was increased, whereas expression for alpha-myosin heavy chain (alphaMHC) and the sarcoplasmic
39 ility, which results from down-regulation of alpha-myosin heavy chain (alphaMHC) and up-regulation of
40              Initial results using the mouse alpha-myosin heavy chain (alphaMHC) promoter resulted in
41                   In this study, we used the alpha-myosin heavy chain (alphaMHC) promoter to generate
42                         CrePR1 driven by the alpha-myosin heavy chain (alphaMHC) promoter was express
43 ompared the gene expression profiles between alpha-myosin heavy chain (alphaMHC)-BMP10 transgenic hea
44                                              alpha-Myosin heavy chain (alphaMHC)-mTORkd mice had a ne
45 use hearts bearing the R403Q mutation in the alpha-myosin heavy chain (alphaMHC403/+).
46 show that YY1 is a negative regulator of the alpha-myosin heavy chain (alphaMyHC) gene, which, with b
47     In vitro, Cre driven by cardiac-specific alpha-myosin heavy chain (alphaMyHC) sequences elicited
48  mice regulated by cardiac lineage promoters alpha-myosin heavy chain (alphaMyHC), Nkx2.5, or Mef2C.
49  is a single-copy transgene controlled by an alpha-myosin heavy chain (aMHC) promoter and coding for
50 d two disease-inducing peptides from cardiac alpha-myosin heavy chain (CAMHC).
51 of the HCM-causing Arg403Gln mutation in the alpha-myosin heavy chain (MHC) gene is inhibited by doxy
52                        The expression of the alpha-myosin heavy chain (MHC) gene is restricted primar
53  the heart using the cardiomyocyte- specific alpha-myosin heavy chain (MHC) promoter led to approxima
54 ights and dimensions and caused a shift from alpha-myosin heavy chain (MHC) to beta-MHC gene expressi
55 tation is a missense substitution, I820N, in alpha-myosin heavy chain (MYH6), a structural protein ex
56 mutations in the actin-binding domain of the alpha-myosin heavy chain (MyHC) gene displays many pheno
57                     T3 and NE also increased alpha-myosin heavy chain (MyHC) mRNA and reduced beta-My
58  generated cardiac-specific MDA5 transgenic (alpha-myosin heavy chain [alphaMHC]-MDA5) mice.
59        As in the left ventricle, decrease in alpha-myosin heavy chain and a switch towards glycolysis
60 he SRF target genes skeletal alpha-actin and alpha-myosin heavy chain and blocked differentiation of
61 the mRNAs encoding the contractile proteins, alpha-myosin heavy chain and cardiac alpha-actin, and th
62  fetal genes, reversing, in part, changes in alpha-myosin heavy chain and sarcoplasmic reticulum Ca2+
63 y method was used to study mice harboring an alpha-myosin heavy chain Arg403Gln missense mutation (al
64 c ablation of SRF by crossing the transgenic alpha-myosin heavy chain Cre recombinase line with SRF L
65 ghtly later deletion of calcineurin with the alpha-myosin heavy chain Cre transgene resulted in letha
66 intracellular reactive oxygen species (ROS), alpha-myosin heavy chain expression (alpha-MHC), and int
67  from embryoid bodies was inhibited, whereas alpha-myosin heavy chain expression and myosin-stained c
68 baseline, accompanied by upregulation of the alpha-myosin heavy chain gene and increases in cardiac f
69  On a soy diet, males with a mutation in the alpha-myosin heavy chain gene progress to dilation and h
70 ene consisting of the cardiomyocyte-specific alpha-myosin heavy chain gene promoter and the A3AR cDNA
71 modulin cDNA was placed under control of the alpha-myosin heavy chain gene promoter to overexpress tr
72 tal muscle TnT transgene driven by a cardiac alpha-myosin heavy chain gene promoter.
73 1B-adrenergic receptor (AR) using the murine alpha-myosin heavy chain gene promoter.
74 y acid transport protein 1 (FATP1) using the alpha-myosin heavy chain gene promoter.
75 the b-type natriuretic peptide gene, and the alpha-myosin heavy chain gene.
76  2.9 kb of 5' flanking sequence from the rat alpha-myosin heavy chain gene.
77                                          The alpha-myosin heavy chain is a principal molecule of the
78                                      We show alpha-myosin heavy chain MerCreMer and the MLC-2v promot
79  myocardium expressed substantial amounts of alpha-myosin heavy chain mRNA (alpha-MHC, 23-34% of tota
80 rcoplasmic-reticulum calcium ATPase mRNA and alpha-myosin heavy chain mRNA and a decrease in beta-myo
81 rozygotes and demonstrated downregulation of alpha-myosin heavy chain only in Gata4/Tbx5 heterozygote
82  induced in BALB/c mice by immunization with alpha-myosin heavy chain peptide and complete Freund's a
83  p406-425 peptide derived from mouse cardiac alpha-myosin heavy chain preferentially develop a predom
84 CIP1) under control of the cardiac-specific, alpha-myosin heavy chain promoter (alpha-MHC).
85  we generated transgenic mice containing the alpha-myosin heavy chain promoter (alphaMHC) placed prox
86 fic expression of PPARgamma is driven by the alpha-myosin heavy chain promoter (alphaMHC-PPARgamma) w
87 the tetracycline-regulated, cardiac-specific alpha-myosin heavy chain promoter (V1A-TG).
88 mice were created using the cardiac-specific alpha-myosin heavy chain promoter and rat A1AR cDNA.
89 essing tamoxifen-inducible Cre driven by the alpha-myosin heavy chain promoter are increasingly used
90 ional regulatory elements located within the alpha-myosin heavy chain promoter can be manipulated to
91 ice expressing ATF3 under the control of the alpha-myosin heavy chain promoter have atrial enlargemen
92 rexpressing human Bcl-2 under the control of alpha-myosin heavy chain promoter into allogenic C57BL/6
93 the Tmod1-null mice under the control of the alpha-myosin heavy chain promoter Tg(alphaMHC-Tmod1).
94                                    Using the alpha-myosin heavy chain promoter to direct cardiac spec
95                          With the use of the alpha-myosin heavy chain promoter to direct cardiac-spec
96                  We used the heart-selective alpha-myosin heavy chain promoter to drive expression in
97                                  We used the alpha-myosin heavy chain promoter to drive expression of
98 nder control of the tetracycline-repressible alpha-myosin heavy chain promoter underwent echocardiogr
99 endogenous ACE gene under the control of the alpha-myosin heavy chain promoter using targeted homolog
100                  This down-regulation of the alpha-myosin heavy chain promoter was accomplished by th
101 skeletal actin promoter 1.7-fold whereas the alpha-myosin heavy chain promoter was unaffected.
102                       The cardiac-restricted alpha-myosin heavy chain promoter was used to target exp
103 the HIF-1alpha gene under the control of the alpha-myosin heavy chain promoter were constructed.
104 oA under the control of the cardiac-specific alpha-myosin heavy chain promoter were generated.
105 e overexpression of iNOS in transgenic mice (alpha-myosin heavy chain promoter) did not induce contra
106 by E11, mediated by Cre under control of the alpha-myosin heavy chain promoter), animals survived to
107 inhibitor for Rho family proteins, using the alpha-myosin heavy chain promoter, active at embryonic d
108 r gene under control of the cardiac-specific alpha-myosin heavy chain promoter, resulting in rhythmic
109 ion beta-tropomyosin mice by turning off the alpha-myosin heavy chain promoter, which is driving the
110 AK) on cardiogenesis in mouse ES cells using alpha-myosin heavy chain promoter-driven enhanced green
111  in which expression was driven by the mouse alpha-myosin heavy chain promoter.
112 ively active mutant of Akt linked to the rat alpha-myosin heavy chain promoter.
113 verexpressing Bcl-2 under the control of the alpha-myosin heavy chain promoter.
114 ATP sensitivity under control of the cardiac alpha-myosin heavy chain promoter.
115 domains (MerCreMer) under the control of the alpha-myosin heavy chain promoter.
116 utant of the PKCepsilon isoform driven by an alpha-myosin heavy chain promoter.
117 r in the hearts of transgenic mice using the alpha-myosin heavy chain promoter.
118 pression of MLC2v was achieved by use of the alpha-myosin heavy chain promoter.
119 A1a in the heart, using the cardiac-specific alpha-myosin heavy chain promoter.
120 IGF-1B was placed under the control of a rat alpha-myosin heavy chain promoter.
121 se specifically in the mouse heart using the alpha-myosin heavy chain promoter.
122 pha coding sequence was driven by the murine alpha-myosin heavy chain promoter.
123  smooth muscle gamma-actin using the cardiac alpha-myosin heavy chain promoter.
124          Expression was driven by the murine alpha-myosin heavy chain promoter.
125 sed wild-type Galphaq in the heart using the alpha-myosin heavy chain promoter.
126 in the heart, driven by the cardiac-specific alpha-myosin heavy chain promoter.
127 GF-1B) was placed under the control of a rat alpha-myosin heavy chain promoter.
128 lear dominant negative CELF protein under an alpha-myosin heavy chain promoter.
129 atal cardiomyocytes under the control of the alpha-myosin heavy chain promoter.
130 atal cardiomyocytes under the control of the alpha-myosin heavy chain promoter.
131 R and constitutively active (ca) mTOR, using alpha-myosin heavy chain promoter.
132 A, each driven by the cardiomyocyte-specific alpha-myosin heavy chain promoter.
133 rexpression of CYP2J2 was achieved using the alpha-myosin heavy chain promoter.
134 ardiomyocytes were generated using the mouse alpha-myosin heavy chain promoter.
135 entricular myocytes under the control of the alpha-myosin heavy chain promoter.
136                 These mice were crossed with alpha-myosin heavy chain reverse transcriptional transac
137                            Downregulation of alpha-myosin heavy chain was restored by the treatment,
138 plasmic reticulum Ca2+-ATPase (SERCA)-2a and alpha-myosin heavy chain were reduced in hypothyroidism,
139 promoters (Skeletal alpha-actin, Desmin, and alpha-Myosin heavy chain) in skeletal and cardiac myocyt
140 as achieved in adult mice using an alphaMHC (alpha-myosin heavy chain)-MerCreMer system.
141 utant mouse model of FHC (Arg403Gln knockin, alpha-myosin heavy chain).
142 se3 was induced by using the rat promoter of alpha-myosin heavy chain, a model that may represent a u
143 cteristic of cardiomyocytes, such as cardiac alpha-myosin heavy chain, cardiac troponin I and T, atri
144 ch as those encoding cardiac alpha-actin and alpha-myosin heavy chain, in an SRF-dependent manner in
145 diac-specific transcripts, including cardiac alpha-myosin heavy chain, troponin C, myosin light chain
146 lt mouse hearts, which predominantly express alpha-myosin heavy chain, we observed high concentration
147 ic promoters, including the alpha-actins and alpha-myosin heavy chain, were selectively and potently
148 n of CLP-1 haplodeficiency in the transgenic alpha-myosin heavy chain-angiotensinogen mice causes pro
149 crossbred into a mouse genetic model of CHF (alpha-myosin heavy chain-calsequestrin), MCK-EcSOD trans
150 cyte-specific LKB1 knock-out (KO) mice using alpha-myosin heavy chain-Cre deletor strain.
151 reviously, we described transgenic mice with alpha-myosin heavy chain-directed expression of a consti
152 art failure based on cardiac phenotypes from alpha-myosin heavy chain-directed overexpression mice.
153 ted cardiac-specific ILK knockout mice using alpha-myosin heavy chain-driven Cre expression.
154  new line of evidence for the differentiated alpha-myosin heavy chain-expressing cardiomyocyte as the
155 ed ZO-1 CM-specific knockout (KO) mice using alpha-Myosin Heavy Chain-nuclear Cre (ZO-1cKO) and inves
156 ven by the promoter for the cardiac-specific alpha-myosin heavy chain.
157 in and indirect targets such as myogenin and alpha-myosin heavy chain.
158 KAG2 gene with the cardiac-specific promoter alpha-myosin heavy chain.
159  DR4-HRE but also in some genes, such as rat alpha-myosin heavy-chain and S14 genes, containing the D
160 -sarcoglycan mutation in the heart using the alpha-myosin heavy-chain gene promoter.
161  The cre recombinase transgene driven by the alpha-myosin heavy-chain promoter deleted the floxed ET(
162 pase has physiological actions, we placed an alpha-myosin heavy-chain promoter upstream of a human li
163  using conditional ROCK2(flox/flox) mice and alpha-myosin heavy-chain promoter-driven Cre recombinase
164 eceptor gamma 1 (PPARgamma1) via the cardiac alpha-myosin heavy-chain promoter.
165 ed and crossed into merCremer mice under the alpha-myosin heavy-chain promoter.
166 inhibitor for Rho family proteins, using the alpha-myosin heavy-chain promoter.
167 rt and skeletal muscle, which indicates that alpha-myosin may be a clinically important autoantigen i
168  of this study was to determine whether fast alpha-myosin molecular motor gene transfer can confer ca
169                                         Fast alpha-myosin motor expression was determined by Western
170 inotropy in failing cardiac myocytes by fast alpha-myosin motor protein gene transfer.
171 osin isoform mRNAs were affected by CAN, but alpha-myosin mRNA was reduced more in nontransgenic mice
172 ic abnormalities in FHC mice with a specific alpha-myosin mutation, and also validate a novel method
173  autoimmune myocarditis by immunization with alpha-myosin-peptide; 20 mice served as controls.
174  three patients with ICI-MC were expanded by alpha-myosin peptides.
175 to insufficient thymic negative selection of alpha-myosin-reactive T cells.
176  recognize the putative cardiac autoantigens alpha-myosin, troponin I or troponin T.
177 etected in nuclear chain fibres, and cardiac alpha-myosin was present in one of the two nuclear bag f
178 quences of either Loop 1+Loop 2 or Loop 2 of alpha-myosin were exchanged for those of beta-myosin wer
179                 The cardiac-specific protein alpha-myosin, which is absent from the thymus(3,4), was

 
Page Top